MDGL•benzinga•
Madrigal Reveals Two-Year Data From Compensated MASH Cirrhosis Arm Of MAESTRO-NAFLD-1 Trial Demonstrating Potential Benefit Of Rezdiffra (resmetirom) In Patients With Compensated MASH Cirrhosis
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 26, 2025 by benzinga